IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Tikehau Investment Management

Tikehau Investment Management reduced its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 8.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,637 shares of the company’s stock after selling 418 shares during the quarter. IDEXX Laboratories comprises approximately 2.4% of Tikehau Investment Management’s investment portfolio, making the stock its 16th largest position. Tikehau Investment Management’s holdings in IDEXX Laboratories were worth $1,917,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Hurley Capital LLC acquired a new stake in shares of IDEXX Laboratories in the fourth quarter valued at approximately $29,000. Rialto Wealth Management LLC acquired a new position in shares of IDEXX Laboratories during the 4th quarter valued at about $30,000. Retirement Wealth Solutions LLC purchased a new stake in shares of IDEXX Laboratories in the fourth quarter valued at about $31,000. Kestra Investment Management LLC purchased a new position in IDEXX Laboratories during the fourth quarter worth about $38,000. Finally, Crews Bank & Trust acquired a new position in IDEXX Laboratories in the 4th quarter valued at about $41,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Insider Buying and Selling

In related news, Director M Anne Szostak sold 3,000 shares of the stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares of the company’s stock, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP George Fennell sold 9,986 shares of the business’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares of the company’s stock, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.98% of the company’s stock.

IDEXX Laboratories Stock Up 2.3 %

Shares of IDEXX Laboratories stock opened at $411.72 on Friday. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $548.88. The company has a 50 day moving average of $422.37 and a 200 day moving average of $430.84. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The company has a market capitalization of $33.37 billion, a P/E ratio of 38.59, a P/E/G ratio of 3.41 and a beta of 1.50.

Analysts Set New Price Targets

IDXX has been the topic of a number of recent analyst reports. Piper Sandler upped their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a report on Monday, February 10th. Barclays boosted their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Stifel Nicolaus reduced their price target on shares of IDEXX Laboratories from $450.00 to $420.00 and set a “hold” rating on the stock in a research note on Monday, April 14th. Morgan Stanley cut their target price on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 29th. Finally, StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, April 12th. Four research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $523.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.